Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margalida Calafat

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 14, 2025
New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicityHugo Tejera-Pérez, Alejandro Velasco-Ruiz, María Chaparro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
Therapeutic Advances in Gastroenterology|June 29, 2026
Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCUInmaculada Alonso-Abreu, Laura Ramos, Alejandro Hernandez-Camba, et al.
Gastroenterologia Y Hepatologia|January 14, 2024
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
The American Journal of Gastroenterology|January 31, 2025
HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA RegistryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
Gastroenterologia Y Hepatologia|November 25, 2023
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
The American Journal of Gastroenterology|July 15, 2024
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
Journal of Crohn'S & Colitis|September 24, 2020
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA RegistryMaría Chaparro, Ana Garre, Francisco Mesonero, et al.
Alimentary Pharmacology & Therapeutics|April 24, 2023
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH studyMaría José Casanova, Óscar Nantes, Pilar Varela, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 14, 2025
New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicityHugo Tejera-Pérez, Alejandro Velasco-Ruiz, María Chaparro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
Therapeutic Advances in Gastroenterology|June 29, 2026
Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCUInmaculada Alonso-Abreu, Laura Ramos, Alejandro Hernandez-Camba, et al.
Gastroenterologia Y Hepatologia|January 14, 2024
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
The American Journal of Gastroenterology|January 31, 2025
HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA RegistryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
Gastroenterologia Y Hepatologia|November 25, 2023
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
The American Journal of Gastroenterology|July 15, 2024
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registryMargalida Calafat, Carles Suria, Francisco Mesonero, et al.
Journal of Crohn'S & Colitis|September 24, 2020
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA RegistryMaría Chaparro, Ana Garre, Francisco Mesonero, et al.
Alimentary Pharmacology & Therapeutics|April 24, 2023
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH studyMaría José Casanova, Óscar Nantes, Pilar Varela, et al.
Pageof 7